The intestinal epithelium undergoes a continual process of proliferation, differentiation and apoptosis. Previously, we have shown that the PI3K/Akt/mTOR pathway has a critical role in intestinal homeostasis. However, the downstream targets mediating the effects of mTOR in intestinal cells are not known. Here, we show that the ketone body β-hydroxybutyrate (βHB), an endogenous inhibitor of histone deacetylases (HDACs) induces intestinal cell differentiation as noted by the increased expression of differentiation markers (Mucin2 (MUC2), lysozyme, IAP, sucrase-isomaltase, KRT20, villin, Caudal-related homeobox transcription factor 2 (CDX2) and p21 Waf1 ). Conversely, knockdown of the ketogenic mitochondrial enzyme hydroxymethylglutaryl CoA synthase 2 (HMGCS2) attenuated spontaneous differentiation in the human colon cancer cell line Caco-2. Overexpression of HMGCS2, which we found is localized specifically in the more differentiated portions of the intestinal mucosa, increased the expression of CDX2, thus further suggesting the contributory role of HMGCS2 in intestinal differentiation. In addition, mice fed a ketogenic diet demonstrated increased differentiation of intestinal cells as noted by an increase in the enterocyte, goblet and Paneth cell lineages. Moreover, we showed that either knockdown of mTOR or inhibition of mTORC1 with rapamycin increases the expression of HMGCS2 in intestinal cells in vitro and in vivo, suggesting a possible cross-talk between mTOR and HMGCS2/βHB signaling in intestinal cells. In contrast, treatment of intestinal cells with βHB or feeding mice with a ketogenic diet inhibits mTOR signaling in intestinal cells. Together, we provide evidence showing that HMGCS2/βHB contributes to intestinal cell differentiation. Our results suggest that mTOR acts cooperatively with HMGCS2/βHB to maintain intestinal homeostasis.
The intestinal epithelium undergoes a process of constant and rapid renewal. The intestinal crypts of Lieberkühn, a highly dynamic niche with multipotent stem cells residing in its lower third, generate new cells that eventually differentiate into the four specialized cell types of the small intestine, namely absorptive enterocytes and secretory lineages known as enteroendocrine, goblet and Paneth cells.
1,2 Differentiated enterocytes, which make up the majority of the cells of the gut mucosa, then undergo a process of apoptosis and are extruded into the lumen. 1, 3 The mechanisms that regulate stem cell maintenance, proliferation, differentiation and apoptosis are precisely orchestrated to ensure proper organ maintenance. 3 An imbalance in this highly regimented and orderly process within the intestinal crypts is associated with a number of intestinal pathologies including colorectal cancer, inflammatory bowel disease and necrotizing enterocolitis. [4] [5] [6] To date, the cellular mechanisms regulating intestinal cell differentiation are not entirely known.
Our previous findings identified a central role for PI3K/Akt/ mTOR in intestinal differentiation and proliferation; [7] [8] [9] [10] however, the downstream mediators have not been entirely elucidated. Metabolic changes are now known to have a pivotal role in dictating whether a cell proliferates, differentiates or remains quiescent. 11 Tissue-and cell-specific metabolic pathways are tightly regulated during development and perform unique functions in specific contexts. 11 Recent findings have also shown that proliferative cells at the base of the intestinal crypt are characterized by a glycolytic metabolic phenotype, whereas differentiated cells have an oxidative phosphorylation phenotype. 12 The short chain fatty acid butyrate, a histone deacetylase (HDAC) inhibitor, is known to promote intestinal cell differentiation. 13 In addition, butyrate has been shown to increase ketone body production through induction of HMGCS2 expression in human intestinal mucosa; 14 many of the effects of butyrate are likely ketone body dependent. 15 The synthesis of ketone bodies, such as β-hydroxybutyrate (βHB) and acetoacetate (AcAc), is controlled by the rate-limiting enzyme, mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2). 16 Recently, βHB has also been shown to act as an endogenous inhibitor of HDACs, 17 which are known to regulate intestinal epithelial differentiation. 18 Circulating concentrations of βHB can increase to as much as 6-8 mM during prolonged fasting and caloric restriction 16, 17 when the liver switches to fatty acid oxidation, and even to 25 mM in diabetic ketoacidosis. These nutritional states are associated with altered intestinal integrity, 19 but it is unknown whether ketone bodies have a role in the maintenance of intestinal homeostasis.
Previously, we reported that the TSC2/mTOR signaling pathway has an important role in the maintenance of intestinal homeostasis. In our current study, we found that intestinal cell differentiation is characterized by increased ketogenesis. Moreover, we show that HMGCS2/βHB has an important role in the maintenance of intestinal epithelium homeostasis. Thus, aberrant regulation of ketogenesis may result in an imbalance in the proliferation, differentiation and apoptosis patterns within the intestinal crypts, which is associated with a number of intestinal pathologies.
Results
Intestinal cell differentiation is characterized by increased ketogenesis. To determine whether proliferating and differentiated cells demonstrate distinct metabolic patterns, we used 13 C-glucose and 13 C-glutamine stable isotope resolved metabolomics (SIRMs) to map metabolic changes in cultured Caco-2 cells as they undergo differentiation. 20 Differentiation of Caco-2 cells elicited pronounced changes in central metabolism involving both glucose and glutamine utilization (Supplementary Figure 1) . Analysis of the media showed that, upon differentiation, there was a marked decrease in glucose consumption and lactic fermentation. In addition, we observed a decrease in consumption of amino acids, particularly glutamine and valine. This is consistent with an overall decrease in metabolic activity as a consequence of differentiation.
Analysis of the intracellular metabolites showed that the decreased steady-state levels of intracellular metabolites, such as citrate and malate, were noted with differentiation (Supplementary Figure 1) . Interestingly, increased amounts of total and of 13 C-enriched βHB were noted in the differentiated cells grown in the presence of [U-
13 C]-glucose. We observed an increase of both m2 and m4 βHB (Supplementary Figure 1 , insert) consistent with condensation of 13 C-enriched acetyl CoA (AcCoA) with either unlabeled AcCoA or glucose-derived 13 C-enriched AcCoA. Furthermore, βHB was not present in significant amounts in the media, suggesting that it is not exported out of the cell, nor was there obvious cell death. These novel findings demonstrate that glucose-derived carbon has entered the pathway acetyl CoA → AcAc → βHB in the differentiated cells and an enhanced ketogenesis occurs with intestinal cell differentiation. In contrast, there was insignificant incorporation of glutamine-derived 13 C into βHB (data not shown).
βHB induces enterocyte differentiation in Caco-2 cells. Caco-2 cells can differentiate into an enterocyte-like phenotype, either with treatment by HDAC inhibitors or spontaneously with overconfluence, characterized by a polarized monolayer and the expression of cytokeratin 20 (KRT20) and the brush-border enzymes such as sucrase-isomaltase (SI). 21, 22 To determine whether βHB has a role in human intestinal cell differentiation, Caco-2 cells were treated with βHB for 48 h and the mRNA levels of the enterocyte markers SI and KRT20 were determined. As shown in Figure 1a , treatment of Caco-2 cells with βHB-induced SI and KRT20 mRNA expression, suggesting that βHB increases enterocyte differentiation. p21
Waf1 inhibits intestinal cell growth and induces differentiation; 23 Caudal-related homeobox transcription factor 2 (CDX2) is an intestine-specific transcription factor regulating homeostasis of the continuously renewing intestinal epithelium. 24 We found that treatment with βHB also increased p21
Waf1 and CDX2 mRNA ( Figure 1a ) and protein expression (Figure 1b) . Furthermore, HDAC inhibition by βHB was shown by the increased acetylation of histone H3 lysine 9 (H3K9ac) (Figure 1b) . Consistent with the increased mRNA expression, treatment with βHB increased KRT20 protein expression in Caco-2 cells (Figure 1b) . These results indicate that βHB, which is increased with intestinal cell differentiation, acts as an endogenous inhibitor of HDACs inducing intestinal cell differentiation.
Knockdown of the ketone biosynthetic enzyme HMGCS2 inhibits enterocyte differentiation in Caco-2 cells. We have shown that treatment with βHB induces enterocytic differentiation in Caco-2 cells and that synthesis of βHB is increased in differentiated Caco-2 cells. βHB synthesis is dependent on the activity of mitochondrial HMGCS2. 25 To determine the role of HMGCS2 in intestinal cell differentiation, we transfected pre-confluent Caco-2 cells with shRNA directed against HMGCS2 mRNA to determine whether loss of HMGCS2 can attenuate the differentiated phenotype associated with post-confluence. Caco-2 cell lines with stable HMGCS2 knockdown were cultured and harvested at different time points: pre-confluent (pre) or 3, 6 and 12 days post-confluent. As shown in Figure 2 , spontaneous Caco-2 differentiation was shown by the increased mRNA expression of SI, KRT20 and p21
Waf1 as determined by real-time RT-PCR (Figure 2a) , and increased protein expression of p21
Waf1 , CDX2 and villin as determined by western blotting ( Figure 2b) ; these increases were significantly attenuated by knockdown of HMGCS2, suggesting that HMGCS2 is required for Caco-2 spontaneous differentiation. In agreement with the increase of βHB, expression of HMGCS2 protein is markedly increased with spontaneous Caco-2 cell differentiation (Figure 2b ).
HMGCS2/βHB contributes to the induction of goblet and Paneth cell marker expression. Treatment with butyrate, an HDAC inhibitor, induces differentiation as noted by the increased expression of intestinal alkaline phosphatase (IAP), an enterocyte differentiation marker, and Mucin2 (MUC2), a goblet cell differentiation marker in LS174T cells. 26, 27 We have shown that βHB inhibits HDAC in Caco-2 cells. To determine whether βHB also increases goblet cell differentiation, we treated LS174T cells with βHB. As shown in Figure 3 , treatment of LS174T with 10 mM βHB increased not only the expression of KRT20 and IAP but also increased the expression of MUC2 and p21
Waf1 and CDX2 (Figures 3a  and b) . The inhibition of HDAC by βHB was demonstrated by increased expression of H3K9ac (Figure 3b ).
To determine whether βHB also contributes to Paneth cell differentiation, we next treated HT29 cells with βHB. HT29 cells produce IAP, and treatment with butyrate increases expression of IAP in HT29 cells. 21 In addition, HT29 cells produce MUC2 9 and lysozyme (LYZ) (a differentiation marker of Paneth cells). 28 Treatment of HT29 cells with βHB increased the mRNA (Figure 4a ) and/or protein levels (Figure 4b ) of IAP, MUC2, LYZ and p21
Waf1 and CDX2 and protein levels of H3K9ac. Taken together, these novel results suggest that βHB is an endogenous inhibitor of HDACs and an inducer of intestinal cell differentiation. To test the effect of βHB on cell proliferation and apoptosis along with the increased differentiation, LS174T and HT29 cells were treated with βHB and cell numbers were counted. βHB treatment inhibited HT29 and LS174T cell proliferation ( Supplementary Figures 2A and B) . There was no apparent increase in apoptosis (as determined by caspase-3 cleavage and DNA fragmentation) after treatment with βHB at same dosages for 48 h (data not shown).
To delineate the role of HMGCS2 in the regulation of intestinal cell differentiation more precisely, we overexpressed HMGCS2 in Caco-2 and LS174T cells. Overexpression of HMGCS2 increased expression of p21
Waf1 , CDX2 and Finally, to correlate the expression pattern of HMGCS2 protein in the human intestine, sections of adjacent normal human small bowel were obtained from five adult patients following intestinal resection for GI pathology (Supplementary Table 1 ). Intense staining for HMGCS2 was localized to the most differentiated region of the intestine (i.e., villus), which correlates with our in vitro results by linking increased HMGCS2 expression with the most highly differentiated region of the intestinal mucosa (Figure 5d ).
Feeding a ketogenic diet to mice enhances intestinal differentiation. We next determined whether the increased ketogenesis enhances the differentiation in the epithelium of mouse intestine. Mice fed with ketogenic diets demonstrate elevated HMGCS2/βHB levels in tissues including the intestine. 29 , 30 1,3-Butanediol, a ketone body precursor, is metabolized by alcohol dehydrogenase and aldehyde dehydrogenases to βHB. 31 We fed mice with a ketogenic diet (normal chow diet mixed with 1,3-butanediol ketone diesters) 30 for 14 days to increase ketogenesis; the intestinal tissues were then harvested for analysis. As shown in Figure 6a , mice fed with the ketogenic diet demonstrated inhibition of HDAC as noted by the increased expression of H3K9ac. Importantly, mice fed with the ketogenic diet showed increased intestinal expression of MUC2 and p21 Waf1 protein, suggesting that ketogenesis contributes to intestinal cell differentiation. Along with the increased differentiation, mTOR signaling was inhibited as shown by the decreased expression of p-S6 (Figure 6a ). Collectively, these results suggest a cross-talk between ketogenesis and mTOR signaling during intestinal cell differentiation. Mice fed with the ketogenic diet increased expression of HMGCS2 in conjunction with decreased mTOR signaling in the small intestine ( Figure 6a ). As inhibition of mTOR has been shown to increase the expression of HMGCS2 mRNA and ketogenesis, 32 feeding a ketogenic diet may increase the expression of HMGCS2 through the inhibition of mTOR signaling in intestinal cells. We did not find increased HMGCS2 expression in the colonic mucosa of mice fed with the ketogenic diet compared with mice fed a normal control chow (Supplementary Figure 3A) . As the level of HMGCS2 is much higher in colon mucosa than that in small bowel mucosa (Supplementary Figure 3B) , it may be difficult to HMGCS2 is specifically expressed in the more differentiated region (i.e., villus; arrows). Scale bars = 50 μm. The images are representative of five cases significantly increase the expression of basal HMGCS2 in the colonic epithelium.
We next determined the effect of increased ketogenesis on intestinal cell differentiation. In mice fed with the ketogenic diet, the intestine appeared normal by histology (Supplementary Figure 4A) . Fast Red staining revealed a marked increase in IAP activity in the small bowel of mice fed with a ketogenic diet (Figure 6b ), demonstrating increased enterocyte differentiation. MUC2 expression was markedly increased in the small bowel of mice fed the ketogenic diet as noted by Alcian blue (AB) staining and IHC (Figures 6c, d and Supplementary Figure 4B) . Moreover, staining the intestinal sections from ketogenic diet-fed mice for LYZ revealed an obvious increase in Paneth cells (Figures 6e and f) . In agreement with the increased CDX2 expression mediated by treatment with βHB or overexpression of HMGCS2, increased expression of CDX2 was detected in the small bowel of mice fed the ketogenic diet (Figure 6g) , demonstrating a ketogenesis-dependent regulation of CDX2. Therefore, results from our in vitro and in vivo studies show that ketogenesis is required for intestinal cell differentiation. Consistent with the decreased phosphorylation of S6 and increased expression of HMGCS2 (Figure 6a) , decreased staining for p-S6 and increased staining for HMGCS2 was also Figures 4C and D) . These results indicate that increased ketogenesis inhibits mTORC1 signaling in the intestinal epithelium.
Cross-talk between mTOR and HMGCS2/βHB in intestinal cells. Previously, we showed that decreased mTOR activity is associated with differentiation. 33 Moreover, we showed that knockdown or inhibition of mTOR increases, whereas activation of mTOR reduces, the levels of intestinal differentiation markers. 9, 33, 34 In this study, we showed that the expression of HMGCS2 is increased in differentiated cells (Figure 5d ). To determine whether mTOR regulates HMGCS2 expression in intestinal cells, HT29 cells were transfected with mTOR siRNA or non-targeting control (NTC). As shown in Figure 7a , knockdown of mTOR increased HMGCS2 expression. To next determine whether mTOR inhibition increases HMGCS2 in vivo, mice were treated with rapamycin (4 mg/kg, i.p., daily for 6 days) and mucosal proteins were extracted from small bowel for analysis of HMGCS2 expression. As shown in Figure 7b , administration of rapamycin inhibited mTOR signaling as noted by the decreased expression of p-S6. Importantly, rapamycin markedly increased HMGCS2 protein expression in intestinal epithelium, demonstrating mTORC1 regulation of HMGCS2 expression in intestinal cells. In agreement with the increased HMGCS2 expression, mice treated with rapamycin showed increased differentiation in intestinal cells (Supplementary Figure 7 Cross-talk between mTORC1 and HMGCS2/βHB signaling. (a) HT29 cells were transfected with NTC or mTOR siRNA. After incubation for 48 h, cells were lysed and western blot analysis was performed using antibodies against HMGCS2, mTOR and β-actin. Knockdown of mTOR increased HMGCS2 expression in HT29 cells. The images are representative of three independent experiments. HMGCS2 signals from three separate experiments were quantitated densitometrically and expressed as fold change with respect to β-actin. (n = 3, data represent mean ± S.D.; *Po0.01 versus NTC siRNA). (b) Mouse small intestinal mucosal protein extracted from mice treated without (control, n = 3) or with rapamycin (n = 3) for 6 days. Western blotting was performed for the expression of the indicated proteins. Each well represents a different mouse from the relevant group. Treatment with rapamycin significantly increased HMGCS2 expression in intestinal epithelium. (c) HT29 cells were treated with βHB at various dosages for 48 h. Cells were lysed and western blot analysis was performed using antibodies against p-S6 and S6. Treatment with βHB inhibited mTOR signaling as shown by the decreased phosphorylation of S6. The images are representative of three independent experiments. (d) LS174T cells were infected with a recombinant adenovirus encoding the human HMGCS2 or vector control encoding GFP. After 48 h, cells were lysed and western blot performed for the detection of the indicated proteins. Overexpression of HMGCS2 inhibited mTOR signaling as shown by the decreased expression of p-S6. p-S6 signals from three separate experiments were quantitated densitometrically and expressed as fold change with respect to total S6. (n = 3, data represent mean ± S.D.; *Po0.01 versus GFP control). The images are representative of three independent experiments. (e) mTOR/HMGCS2/βHB pathway model. Inhibition of mTORC1 increases ketogenesis and contributes to intestinal cell differentiation. In contrast, increase in ketogenesis inhibits mTOR signaling and induces differentiation. mTORC1 acts cooperatively with HMGCS2/βHB to maintain intestinal homeostasis Figure 5 ), which is consistent with our previous findings showing that inhibition of mTOR by rapamycin increases differentiation in mouse intestinal epithelium. 34 Finally, to determine whether the endogenous HDAC inhibitor βHB inhibits mTOR, HT29 cells were treated with βHB for 48 h. As shown in Figure 7c , βHB inhibited mTOR signaling as noted by the dose-dependent decrease in the expression of p-S6. βHB-induced inhibition of mTOR signaling was also noted in FHs 74 Int human small intestinal epithelial cells (Supplementary Figure 6) . As a result of mTOR inhibition, treatment with βHB increased HMGCS2 in FHs 74 Int cells (Supplementary Figure 6) . Moreover, overexpression of HMGCS2 inhibited mTOR signaling in LS174T cells (Figure 7d ). Taken together, our results identify a potential cross-talk between ketogenesis and mTOR signaling, which contributes to the process of intestinal cell differentiation.
Discussion
Previously, we have shown that inhibition of the PI3K/Akt/ mTOR signaling pathway increases intestinal cell differentiation. 9, 13, 21, 33, 34 In our present study, we show that the enrichment of the ketone body, βHB, and expression of the ketogenic enzyme, HMGCS2, was increased in differentiated intestinal cells. Consistent with these results, treatment with βHB increased, whereas knockdown of HMGCS2 inhibited, intestinal cell differentiation. Treatment with βHB or overexpression of HMGCS2 resulted in the induction of CDX2 expression and inhibition of mTOR signaling. Mice fed with a ketogenic diet show an induction of CDX2 and inhibition of mTORC1 signaling along with an increase in intestinal cell differentiation. Taken together, our results suggest that enhanced ketogenesis contributes to the process of intestinal cell differentiation.
We found that treatment with βHB, which was enriched in differentiated cells, induces differentiation, thus suggesting that βHB acts as an endogenous regulator of intestinal homeostasis. Inhibition of HDACs contributes to intestinal cell differentiation. 13, 18 In our current study, we show that βHB inhibits HDACs in intestinal cells. Indeed, βHB acts as an endogenous inhibitor of HDACs in vitro and in vivo. 17 Similar to butyrate, βHB is known to inhibit class I and IIa HDACs with an IC50 of 2-5 mM. 17, 35 An early event in the terminal differentiation of cells is their withdrawal from the cell cycle. 36 Butyrate has been shown to potently suppress intestinal cell proliferation by acting as an HDAC inhibitor. 37 Our previous study showed that butyrate increases p21
Waf1 expression and induces cell cycle arrest associated with intestinal cell differentiation. 13 Similar to butyrate, we found that βHB, acting as an endogenous inhibitor of HDACs, induces p21 Waf1 expression and inhibits intestinal cell proliferation associated with the induction of differentiation. Given the extensive gene regulation by HDACs and the important role of HDACs in regulating intestinal cell differentiation, 38, 39 βHB likely induces intestinal cell differentiation through inhibition of HDACs.
CDX2 is an intestine-specific transcription factor that is essential for the development and maintenance of the intestinal mucosal epithelium. 24 CDX2 is essential for differentiation of gut stem cells into the four intestinal cell types. 40 Ablation of Cdx2 in the intestine results in a decrease of mature enterocytes, and loss of goblet, enteroendocrine and Paneth cells. 41 We showed that treatment with βHB or overexpression of ketogenic enzyme HMGCS2 increased CDX2 expression in intestinal cells. Moreover, our results showed that increased ketogenesis resulted in increased CDX2 expression along with increased differentiation in the intestinal epithelium of mice. Results from our in vitro and in vivo studies suggested that ketogenesis modulates intestinal differentiation through the induction of CDX2 expression. Our previous study demonstrated that treatment with butyrate, an inhibitor of HDAC, increased CDX2 expression in HT29 and Caco-2 cells. 42 Butyrate has been shown to increase ketone body production through induction of HMGCS2 expression in human intestinal mucosa.
14 βHB, acting as the causal agent for differentiation of intestinal cells exposed to butyrate, is supported by the fact that exposure of intestinal cells to βHB results in the terminal differentiation of these cells. As p21
Waf1 is a CDX2 target gene, 43 HMGCS2/ βHB increases p21
Waf1 expression likely through the induction of CDX in intestinal cells, thus contributing to the differentiation process.
We have shown the importance of the PI3K/Akt/mTOR pathway in the regulation of intestinal cell proliferation and differentiation. 7, 13, 44, 45 However, the precise mechanisms of how mTOR regulates intestinal cell proliferation and differentiation remain to be fully defined. We found that HMGCS2/ βHB contributes to intestinal differentiation and, importantly, that inhibition of mTOR signaling increases expression of the ketogenic enzyme HMGCS2 in intestinal cells in vitro and in vivo. Our present results suggest that mTOR regulates intestinal differentiation, at least in part, through the regulation of ketogenesis. mTOR controls the expression of HMGCS2 mRNA and ketogenesis in liver cells through the inhibition of PPARα -dependent transcription. 32 Moreover, HMGCS2 is a direct target of c-Myc, which represses HMGCS2 transcriptional activity in intestinal cells. 46 As activation of mTOR increases c-Myc expression in intestinal cells, 47 it is likely that mTOR inhibition induces HMGCS2 through the alterations of PPARα-and c-Myc-dependent functions in intestinal cells. Our data also showed that treatment with βHB or overexpression of HMGCS2 in vitro, or induction in ketogenesis in vivo, resulted in the inhibition of mTOR signaling in intestinal cells. The inhibition of mTOR by ketone bodies was also demonstrated in the hippocampus and liver of rats fed ketogenic diet. 48 Results from our laboratory and others have shown that inhibition of HDAC inhibits mTOR signaling in various cell types including intestinal cells. 33, 49, 50 As βHB is an endogenous inhibitor of HDAC, it is likely that HMGCS2/βHB inhibits mTOR signaling through the inhibition of HDACs in intestinal cells. Together, our results show that PI3K/Akt/mTOR signaling functions cooperatively with HMGCS2/βHB in the regulation of intestinal cell differentiation.
Our results showed that knockdown of HMGCS2 attenuated the spontaneous differentiation in Caco-2 cells. These results further suggest that HMGCS2 is important for the maintenance of both colon and small intestinal cell homeostasis. The highly expressed HMGCS2 in colon epithelial cells noted in our current study suggests that colon is a ketogenic organ. Ketone bodies produced in colon, not only function as signaling molecules contributing to maintenance of colon epithelial cell differentiation, but may also enter into circulation and effect on the cells in other organs including small intestine. Therefore, perturbed expression of HMGCS2 in intestinal cells will result in the impaired intestinal cell differentiation. Increased differentiation in small intestine is an important mechanism during intestinal adaptation after small bowel resection. 51 In addition, dysregulation of intestinal cell differentiation is associated with inflammatory bowel diseases and colorectal cancer. 4, 5 Indeed, HMGCS2 protein expression is downregulated preferentially in moderately and poorly differentiated colorectal adenocarcinomas. 46 Moreover, we showed that βHB inhibits HT29 and LS174T cell growth. Taken together, these results suggest that ketogenesis not only contributes to intestinal cell differentiation but may also inhibit abnormal growth of intestinal cells. Delineating the role of ketogenesis in the maintenance of intestinal homeostasis is crucial to our understanding of gut development and adaptation.
In conclusion, we show that ketogenesis contributes to intestinal cell differentiation, thus providing a better mechanistic understanding of ketogenesis and its potential beneficial effects in certain intestinal diseases. Taken together, our data support a novel role of ketogenesis, which acts cooperatively with mTOR signaling, in the regulation and the maintenance of intestinal epithelial homeostasis (Figure 7e ).
Materials and Methods
Cell culture, transfection and treatments. The human colon cancer cell lines, HT29 and Caco-2, were purchased from ATCC (Manassas, VA, USA) and were maintained in McCoy's 5A supplemented with 10% fetal calf serum (FCS), and MEM supplemented with 15% FCS, respectively. HT29 and Caco-2 cells were tested for authentication via STR profiling in February 2016 by Genetica DNA Laboratories (LabCorp Specialty Testing Group; Burlington, NC, USA). Authentications were confirmed by a 100% match in comparison with the reference STR profiles from ATCC. In addition, both cell lines were tested for mycoplasma contamination by Genetica DNA Laboratories (LabCorp Specialty Testing Group) and were found to be negative. The human colon cancer cell line, LS174T, purchased in February 2016 from ATCC, was maintained in MEM supplemented with 10% FCS. FHs 74 Int human small intestinal epithelial cells were purchased in July 2016 from ATCC and maintained in Hybri-Care Medium ATCC 46-X supplemented with 30 ng/ml epidermal growth factor (Sigma-Aldrich) and 10% FBS. Caco-2, LS174T and HT29 cell lines have served as useful models to delineate potential pathways leading to differentiation of enterocytes (characterized by expression of the brush-border enzymes IAP and SI, villin, and Keratin 20 (KRT20)), 8, 21, 52 goblet cells (characterized by the increased MUC2 expression in HT29 and LS174T cells), 9, 34 and Paneth cells as shown by the induction of LYZ in HT29 cells. 28 MISSION control shRNA and shRNAs to human HMGCS2 constructed in pLKO.1-puro vector were purchased from Sigma-Aldrich. The control shRNA (non-target shRNA control transduction particles, # SHC002V) contains four base-pair mismatches within the short-hairpin sequence to any known human or mouse genes. The lentivirus-mediated delivery of shRNA was carried out as we have previously described. 9 Adenovirus vectors encoding GFP (Ad-GFP; control) and human HMGCS2 were from Vector BioLabs (Malvern, PA, USA). Flagtagged human HMGCS2 was from Origene (Rockville, MD, USA). Caco-2 cells were infected with the control shRNA or shRNA to human HMGCS2 lentiviral particles, and stably expressing cells were selected with puromycin (5 μg/ml). Human mTOR and NTC siRNA SMARTpool were purchased from Dharmacon, Inc. (Lafayette, CO, USA). HT29 cells were transfected with NTC or mTOR siRNA as we have previously described. 34 SIRM analysis. Caco-2 cells were grown to different levels of confluency in MEM media containing 15% dialyzed FBS and 0.2% [U- N]-glutamine. The medium was sampled at 0, 3, 6, 9 and 24 h from each plate. Cells were quenched and harvested on the plate, and extracted and analyzed as described. 20 The polar and non-polar components were prepared for NMR and mass spectrometry analyses as previously described. 20 NMR spectra were recorded at 14.1 T on an Agilent DD2 spectrometer (Agilent Technologies, Santa Clara, CA, USA) equipped with automation and a 3 mm HCN cold probe. 1D proton spectra were recorded with an acquisition time of 2 s and a recycle time of 6 s with preset for solvent suppression.
13
C-edited 1D HSQC spectra were recorded with an acquisition time of 0.2 s and a recycle time of 2 s, with adiabatic decoupling during the acquisition time. NMR signals were assigned according to in-house databases. Metabolites were quantified by peak integration and comparison with the internal standard DSS with corrections for partial saturation. GC-MS was carried out on samples derivatized with MTBSTFA using a Thermo LTQ (Thermo Fisher Scientific, Austin, TX, USA) GC-MS. Metabolites in GC-MS were assigned from their retention time and mass.
Western blot analysis. Total protein was resolved on a 10% polyacrylamide gel and transferred to polyvinylidene fluoride membranes. Membranes were incubated for 1 h at room temperature in blotting solution. Antibodies to CDX2 (#3977), mTOR (#2983), phospho-S6 (pS235/236, #4858), S6 (#2317), acetylhistone H3 (Lys9, #9649) and p21
Waf1 (# 2947, used for human cell lines) (all from Cell Signaling, Beverly, MA, USA), p21
Waf1 (sc-397, used for mouse tissues, Santa Cruz, Dallas, TX, USA), MUC2 (S-1461, Epitomics Inc., Burlingame, CA, USA), villin (sc-7672, Santa Cruz), KRT20 (ab854, Abcam, Cambridge, MA, USA), HMGCS2 (ab137043, Abcam), Flag (F7425, Sigma, St. Louis, MO, USA) and β-actin (A1978, Sigma) were added, and following blotting with a horseradish peroxidase-conjugated secondary antibody, protein expression was visualized using an enhanced chemiluminescence (ECL) detection system.
Quantitative real-time RT-PCR analysis. Total RNA was extracted and treated with DNase (RQ1, Promega, Madison, WI, USA). Synthesis of cDNA was performed with 1 μg of total RNA using reagents in the TaqMan Reverse Transcription Reagents Kit (ABI, Applied Biosystems Inc., Foster City, CA, USA, #N8080234). TaqMan probe and primers for human SI, IAP, KRT20, MUC2, LYZ, p21 Waf1 , CDX2 and GAPDH were purchased from Applied Biosystems (Foster City, CA, USA). Quantitative real-time RT-PCR analysis was performed with an Applied Biosystems Prism 7000HT Sequence Detection System using TaqMan universal PCR master mix as we have described previously.
9,10
Immunohistochemistry, AB staining and IAP staining. Immunohistochemistry (IHC) and AB staining were performed as we have described previously. 34 Tissue was processed for routine IHC staining using the following antibodies: rabbit anti-LYZ (Diagnostic BioSystems, Pleasanton, CA, USA, RP 028-05), anti-MUC2 (Santa Cruz, SC15334), anti-phospho-S6 (pS235/236) (Cell Signaling, #4858), and anti-CDX2 (Biogenex, Fremont, CA, USA, MU392A-UC). Negative controls (including no primary antibody or isotype-matched mouse immunoglobulin G) were used in each assessment. AB staining was performed according to standard protocol using AB pH 2.5 Stain Kit (Dako, Carpinteria, CA, USA, AR160). IAP staining was performed using Vulcan Fast Red Chromogen kit (Biocare Medical, Concord, CA, USA, FR805), following the manufacturer's recommendations. Formalin-fixed, paraffin-embedded tissue samples of normal human small bowel were used for HMGCS2 staining using anti-HMGCS2 antibody (ab137043, Abcam).
Mice. C57BL/6 mice were obtained from the Jackson Laboratory (Sacramento, CA, USA) and bred in our facility. Mice were maintained on a 12-h light/dark schedule in filter top isolators with autoclaved water under specific pathogen-free conditions, and fed autoclaved standard laboratory chow ad libitum (2918 Teklad Rodent Diet (Envigo, Indianapolis, IN, USA) consisting of 6.2% fat, 18% protein and 44% carbohydrate wt/wt). Six mice (male, 16 weeks) were randomized to control versus rapamycin groups. Rapamycin (LC Laboratories, Woburn, MA, USA), administered by i.p. injection daily for 6 days at 4 mg/kg, was reconstituted in absolute ethanol at 10 mg/ml and diluted in 5% Tween 80 (Sigma) and 5% PEG-400 (Hampton Research, Aliso Viejo, CA, USA) before injection as we described previously. 34 To model a ketogenic diet and elevate ketogenesis in vivo, we fed mice with 1,3-butanediol ketone diesters. 30 Ten mice (male, 16 weeks) were randomized to control diet versus ketogenic diet groups. To prepare the ketogenic diet, standard chow food pellets were ground in a mixer, 200 g of ground diet was mixed with 50 ml of ( ± )-1,3-Butanediol (B84785, Sigma-Aldrich) and shaken to form round pellets. Mice were fed with control normal chow diet or the ketogenic diet ad libitum for 14 days; normal chow and ketogenic diet were refreshed every 72 h.
The ileum and cecum were harvested, opened and washed with ice-cold PBS. Half of the sample was used for IHC; the mucosa from the other portion was scraped with glass slides, placed into cell lysis buffer and immediately snap frozen in liquid N 2 . Samples were homogenized in cell lysis buffer by stainless steel blend bead beating (0.9-2.0 mm; 5 m, 4°C) using a Bullet Blender (Next Advance Inc., Averill Park, NY, USA). Cell lysis buffer (Cell Signaling) was supplemented with 1 mM PMSF and protease inhibitor cocktails (complete mini and complete ultra, EDTA-free; 1 tablet per 10 ml lysis buffer; Roche, Indianapolis, IN, USA). All animal procedures were conducted with approval and in compliance with University of Kentucky Institutional Animal Care and Use Committee.
Statistical analysis. Comparisons of the number of AB + and LYZ + in the intestine were performed between control diet and ketogenic diet mice using the linear mixed model to account for multiple observations from multiple crypts per mouse. Pairwise comparisons for two groups were performed using two-sample t-test or analysis of variance for multiple groups with contrast statements. Adjustment in P-values because of multiple pairwise testing between groups was performed using the Holm's step-down procedure. Comparisons were performed for control versus βHB treatment, control shRNA versus HMGCS2 shRNA, or GFP versus HMGCS2. Bar graphs represent mean ± S.D. levels in each group. P-values o0.05 were considered statistically significant.
For the in vivo mice study, sufficient sample size was utilized to provide at least 80% power to detect a large effect size (1.8 mean differences in S.D. units) based on a two-group comparison, two-sided test with 5% significance level. All data from animal samples with measurement of study endpoints were included in the analysis. Mice within a cage were randomized to both groups in the experiment to ensure balance in treatment group assignments across all cages. The animals were randomly selected for group assignment without preference to size or other confounding factors. A different individual performed measurements on study endpoints to ensure blinding from group assignment. Furthermore, only animal IDs without information on group assignment were available to staff performing the endpoint evaluation. Parametric tests were utilized after evaluating distribution of data (e.g., percentiles, mean and median levels), test for normality (e.g., KolmogorovSmirnov test, if sufficient sample sizes) and test for homogeneity of variance assumptions across groups (folded F-test, Brown-Forsythe test).
